AT&T INC. (T) Stock News

Rosen Law Firm is urging investors in Black Rock Coffee Bar, Inc. (NASDAQ: BRCB) to join a securities class action lawsuit with an August 17, 2026 deadline for lead plaintiff claims. The lawsuit alleges that defendants made materially false statements and failed to disclose that new store openings were cannibalizing existing revenue through 'sales transfer,' which materially impacted financial results during the class period from September 12, 2025 to May 12, 2026.

Rosen Law Firm is urging investors who purchased Futu Holdings Limited securities between May 24, 2023 and May 27, 2026 to join a class action lawsuit. The lawsuit alleges that Futu made false statements and failed to disclose non-compliance with China Securities Regulatory Commission requirements, including conducting securities and futures business without proper licenses, which led to overstated financial results.

CrowdStrike and Snowflake are compared as AI-driven enterprise software leaders. CrowdStrike offers cloud-native cybersecurity with a recurring subscription model, reporting ~21.7% revenue growth and near-profitability. Snowflake provides an AI Data Cloud platform with a consumption-based model, showing ~29.2% revenue growth but deeper losses and higher debt. The article recommends CrowdStrike for 2026 due to its more stable recurring revenue model and profitability, despite both trading at premium valuations.

As Meta and other tech giants rapidly expand AI data center capacity, industrial suppliers Caterpillar and Eaton are experiencing significant growth. Caterpillar's backlog reached a record $63 billion (up 79% year-over-year) driven by demand for earth-moving equipment and power generators, while Eaton's Americas division backlog grew over 40% with order growth at 60%, fueled by AI infrastructure demand. Both companies are well-positioned to benefit from the ongoing data center construction boom, though their valuations are elevated at 45x and 38x P/E ratios respectively.

Chubb, the world's largest publicly traded property and casualty insurer, trades at a 12x P/E ratio compared to the S&P 500's 32x multiple, suggesting potential undervaluation. The company has delivered 226% total returns over the past decade and expects continued growth through middle-market expansion, AI upgrades, and higher fixed-income yields. With a 33-year dividend increase streak and a $7.5 billion buyback authorization, Chubb appears to be a stable, defensive investment opportunity.

The article compares two healthcare ETFs: IHE (U.S. Pharmaceuticals) and IXJ (Global Healthcare). IHE offers concentrated exposure to 56 U.S. pharmaceutical companies with higher recent returns (50.30% 1-yr), but carries significant concentration risk with its top two holdings (J&J and Eli Lilly) comprising 43% of the portfolio. IXJ provides broader diversification across 110 international healthcare companies including medical devices and services, with lower concentration risk but more modest recent returns (18.20% 1-yr). The article suggests IXJ is better for diversification-focused investors, while IHE's outperformance is largely driven by GLP-1 weight-loss drug success.

Rosen Law Firm is notifying investors who purchased Erasca, Inc. (ERAS) stock between January 14, 2025 and April 26, 2026 about a securities class action lawsuit. The lawsuit alleges that Erasca and its executives made false and misleading statements about its lead oncology drug candidate ERAS-0015, including improper comparisons to a competing drug and undisclosed patent disputes. The deadline to serve as lead plaintiff is August 10, 2026.

SpaceX could deliver a 10x return if annual revenue reaches $3.6 trillion by 2040, aligning with Morgan Stanley's $3.4 trillion projection. Currently trading at $1.8 trillion market cap with $18.7 billion in 2025 revenue, the company would need a 5x price-to-sales ratio to reach an $18 trillion valuation. However, this scenario depends on successful execution of Starlink, Starship, and AI segments, with significant downside risk if any underperforms.

Rosen Law Firm is soliciting investors who purchased securities in Verra Mobility Corporation, Hub Group, Inc., and Via Transportation, Inc. during specified periods to join class action lawsuits. The firm alleges that Verra made materially false statements regarding its relationship with Avis Budget Group and concealed adverse facts about potential competition from in-house solutions.

Intuitive Surgical's stock fell this week despite beating Q2 earnings expectations with 19% revenue growth and 25% adjusted net income growth. The decline was triggered by management's decision not to raise full-year guidance, signaling slower growth ahead. Wall Street responded with multiple price target cuts as investors sold shares.

Meta shares surged 21% in July, adding $270 billion to its market cap, driven by the launch of its new cloud computing division under the Meta Compute initiative. The company plans to monetize excess AI infrastructure by selling unused compute resources to outside customers, addressing concerns about aggressive AI spending ($125-145 billion annually). Investors are optimistic about this strategic pivot to generate returns on massive capex investments, though the company's ability to deliver on AI ROI expectations remains critical.

Nvidia CEO Jensen Huang highlighted at CES 2026 that memory is becoming the critical bottleneck in AI development as large language models require increasing storage capacity. Memory and storage chip manufacturers Micron Technology and Sandisk have significantly outperformed Nvidia's stock since then, with both companies reporting surging revenues driven by AI infrastructure demand. Both companies are securing long-term customer contracts worth billions to stabilize their typically cyclical business.

4D Molecular Therapeutics (4DMT) announced positive 2-year results from its PRISM Phase 2b clinical trial of 4D-150, an intravitreal gene therapy for wet age-related macular degeneration (AMD). The single-dose treatment demonstrated consistent maintenance of visual acuity and anatomic control with 78-87% reduction in treatment burden compared to standard aflibercept injections. The therapy was well-tolerated with no new safety concerns or intraocular inflammation cases beyond the first 6 months.

JPMorgan Chase and Goldman Sachs reported strong Q2 earnings driven by investment banking growth. CEO Jamie Dimon projects AI spending will reach over $1 trillion in 2027, up from $700 billion in 2026, signaling continued economic expansion fueled by AI infrastructure investment.

Two Vanguard ETFs are outperforming the S&P 500 this year: the Information Technology ETF (VGT), up 21% driven by semiconductor companies benefiting from AI demand, and the Energy ETF (VDE), benefiting from Middle East conflicts and elevated energy prices. Both ETFs are concentrated in top holdings but positioned to finish ahead of the S&P 500.

Pershing Square USA, Bill Ackman's closed-end fund, is trading at a 20% discount to its net asset value (NAV) since its IPO. Unlike Berkshire Hathaway, which is an operating company, Pershing Square USA is a closed-end fund that trades on exchanges based on supply and demand. While the discount may seem attractive, investors should understand that closed-end funds often trade at discounts for extended periods, and the discount alone shouldn't be the sole reason for investment.

Two US service members in Jordan killed in Iranian attack, US says  Reuters

The Milton Hershey School Trust sold 30,000 shares of Hershey Company stock for approximately $5.2 million on July 13-14, 2026, at weighted-average prices ranging from $169.44 to $177.64 per share. The trust retains substantial ownership with ~1.3 million common shares and ~54.6 million Class B shares. The transaction is characterized as routine portfolio management and should not concern investors. Hershey faces headwinds from cocoa prices and GLP-1 medicines but trades at a reasonable 20x forward earnings with a 3.4% dividend yield.

Iran's Supreme Leader says US breaches show Trump's signature is 'worthless'  Reuters

Vanguard S&P 500 Growth ETF (VOOG) is recommended over Vanguard Mega Cap Growth ETF (MGK) for long-term investors. While MGK offers a slightly lower expense ratio of 0.05% versus VOOG's 0.07%, VOOG's broader diversification across 148 holdings versus MGK's 56 holdings has delivered superior returns across most time periods, with VOOG returning 22.80% over one year compared to MGK's 18.80%.

The Vanguard S&P 500 ETF offers a simple, low-cost way to build wealth through consistent long-term investing in 500 large U.S. companies. With a 0.03% expense ratio and historical 15% average annual returns, investing $500 monthly could yield $1.36 million over 30 years. However, investors should be aware of market volatility, tech sector concentration, and the need for patience and a diversified portfolio strategy.

A securities fraud class action lawsuit has been filed against Zoetis Inc. for allegedly making materially false statements about product adoption during the class period of January 14, 2025 through May 6, 2026. The lawsuit alleges the company misrepresented the performance of key products including Librela, Simparica Trio, Apoquel, and Cytopoint. Zoetis's stock fell 21.5% on May 7, 2026, following disappointing first quarter results showing significant decline in its Companion Animal business. Investors have until July 27, 2026, to file for lead plaintiff status.

Wall Street analysts are bullish on Viking Therapeutics (VKTX), with a consensus price target of $91 representing a potential 150% return. The optimism centers on VK2735, a dual-formulation weight-loss drug showing promising phase 2 efficacy data. However, key phase 3 results won't arrive until late 2027-2028, and some phase 2 oral trial tolerability concerns exist. Cautious investors may want to wait for upcoming maintenance trial results before investing.

Pfizer's attractive 7% dividend yield masks significant risks as the company faces a patent cliff with major drugs losing protection in 2027-2028. With a dividend payout ratio over 130% and limited new drug candidates in the pipeline, investors are concerned about the sustainability of the dividend. However, the company has cash reserves and debt options to maintain payments, and management has prioritized dividend preservation.

Deanna Goodwin, a Board of Directors member at Oceaneering International, sold 7,000 shares (~$285,000) on July 1, 2026, at $40.69 per share, reducing her direct holdings by 16.32%. The sale occurred near recent highs as the stock was up 80.84% over one year. Despite the sale, Goodwin retained nearly 36,000 shares, suggesting continued confidence in the company's long-term prospects amid strong business developments including $1 billion in customer orders.

Rosen Law Firm is urging investors who purchased Via Transportation, Inc. (NYSE: VIA) stock during its IPO to join a securities class action lawsuit before the August 10, 2026 deadline. The lawsuit alleges that Via's IPO offering documents were false and misleading, omitting information about declining Platform Annual Run-Rate Revenue and growth obstacles in Germany. Via's stock has declined approximately 70% from its IPO price to $14.52.

A securities class action lawsuit has been filed against AeroVironment, Inc. (AVAV) alleging the company made false and misleading statements regarding competition for U.S. Space Force contracts (SCAR and SCN programs). Investors who purchased securities between June 25, 2025 and March 10, 2026 may be eligible for compensation. The lead plaintiff deadline is July 27, 2026.

The Schwab U.S. Dividend Equity ETF (SCHD) has returned approximately 20% in 2026, outperforming both the S&P 500 and Nasdaq-100. The $95 billion fund focuses on companies with at least 10 consecutive years of dividend payments and screens for quality fundamentals. Its concentration in healthcare and consumer staples has benefited from a market rotation away from expensive AI and software stocks, though the fund's long-term job is delivering growing income from durable businesses rather than outrunning growth indexes.

NextEra Energy plans to invest $59 billion annually through 2032, with its acquisition of Dominion Energy positioning the combined company to capitalize on expected 60% growth in electricity demand by 2045. The capital spending is projected to support 9%+ annualized earnings growth and enable the company to maintain its decades-long dividend increase streak, making it attractive for dividend growth investors.

The article compares Salesforce and CrowdStrike as investment options in 2026. Salesforce, a mature CRM leader with $41.5B revenue and 10% growth, trades at a 12.1x forward P/E with strong profitability (18% net margin). CrowdStrike, a high-growth cybersecurity firm with $4.8B revenue and 22% growth, trades at 165.5x forward P/E but remains unprofitable (-3% net margin). Despite CrowdStrike's superior growth and market necessity, the author recommends Salesforce as the better buy due to its significantly lower valuation and recent positive momentum in AI offerings, suggesting potential stock recovery.